MedTrace Logo

Vtama in Psoriasis Patients Being Treated With Biologics.

NCT06103695 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-10-27

No results posted yet for this study

Summary

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

Conditions

Interventions

DRUG

Tapinarof

Add on Vtama (tapinarof) to biololgic therapy

Sponsors & Collaborators

  • Psoriasis Treatment Center of Central New Jersey

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2023-10-18
Completion
2023-10-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06103695 on ClinicalTrials.gov